Gemvax

A placebo-controlled study to evaluate the effect, safety and Efficacy of GV1001 in participants with mild to moderate AD.

To be eligible for this study, a potential participant must:

• Be between the ages of 55 and 85
• Study partner during study
• Mild to moderate Dementia